MCID: PPL002
MIFTS: 45

Papillary Carcinoma

Categories: Cancer diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Papillary Carcinoma

MalaCards integrated aliases for Papillary Carcinoma:

Name: Papillary Carcinoma 11 14 16
Carcinoma, Papillary 43 71
Carcinoma Papillary 53

Classifications:



External Ids:

Disease Ontology 11 DOID:3113
MeSH 43 D002291
NCIt 49 C2927
SNOMED-CT 68 25910003
UMLS 71 C0007133

Summaries for Papillary Carcinoma

Disease Ontology: 11 A carcinoma that is derives from epithelial cells with finger like projections.

MalaCards based summary: Papillary Carcinoma, also known as carcinoma, papillary, is related to breast papillary carcinoma and papillary serous adenocarcinoma. An important gene associated with Papillary Carcinoma is CCDC6 (Coiled-Coil Domain Containing 6), and among its related pathways/superpathways are Hepatocyte growth factor receptor signaling and Cytoskeletal Signaling. The drugs BCG vaccine and Mitomycin have been mentioned in the context of this disorder. Affiliated tissues include thyroid, lymph node and breast, and related phenotypes are homeostasis/metabolism and nervous system

Related Diseases for Papillary Carcinoma

Diseases related to Papillary Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 761)
# Related Disease Score Top Affiliating Genes
1 breast papillary carcinoma 32.8 KRT7 ESR1 ERBB2
2 papillary serous adenocarcinoma 32.4 KRT7 ESR1 ERBB2
3 multicentric papillary thyroid carcinoma 32.3 TG RET
4 thyroid carcinoma 32.3 TG RET BRAF
5 tall cell variant papillary carcinoma 32.2 TG RET NKX2-1 MET LGALS3 KRT19
6 nonencapsulated sclerosing carcinoma 32.1 TPO TG RET CALCA
7 thyroid cancer, nonmedullary, 2 31.9 TSHR TG LGALS3 CALCA BRAF
8 hypothyroidism, congenital, nongoitrous, 2 31.4 TSHR TG NKX2-1
9 renal cell carcinoma, nonpapillary 31.4 RET PBRM1 NKX2-1 MUC1 MET KRT7
10 ductal carcinoma in situ 31.3 MUC1 ESR1 ERBB2
11 thyroiditis 31.3 TSHR TPO TG RET CALCA
12 graves disease 1 31.2 TSHR TPO TG CALCA
13 differentiated thyroid carcinoma 31.1 RET NKX2-1 NCOA4 CCDC6 BRAF
14 serous cystadenocarcinoma 31.1 KRT7 ESR1 ERBB2
15 papillary adenocarcinoma 31.1 TG NKX2-1 MUC1 KRT7 ERBB2
16 parathyroid adenoma 31.0 TG RET LGALS3 CALCA
17 thyroid carcinoma, familial medullary 31.0 TG RET NKX2-1 CALCA BRAF
18 goiter 30.9 TSHR TPO TG RET NKX2-1 LGALS3
19 benign mesothelioma 30.9 NKX2-1 KRT7 KRT20 KRT19
20 thyroid gland medullary carcinoma 30.9 TG RET NKX2-1 NCOA4 CCDC6 CALCA
21 breast ductal carcinoma 30.9 MUC1 MET KRT7 KRT19 ESR1 ERBB2
22 intraductal papilloma 30.8 KRT7 ESR1 ERBB2
23 adenoma 30.8 TSHR TG RET MUC1 LGALS3 KRT7
24 hyperthyroidism 30.8 TSHR TPO TG CALCA
25 hashimoto thyroiditis 30.8 TSHR TPO TG RET NCOA4 LGALS3
26 transitional cell carcinoma 30.7 KRT7 KRT20 KRT19 ERBB2
27 multiple endocrine neoplasia 30.7 TG RET CALCA
28 mucoepidermoid carcinoma 30.6 TG MUC1 KRT7 KRT19 CALCA
29 hypothyroidism 30.6 TSHR TPO TG RET NKX2-1 LGALS3
30 adenocarcinoma 30.6 RET NKX2-1 MUC1 MET KRT7 KRT20
31 nontoxic goiter 30.6 TSHR TPO TG CALCA
32 follicular adenoma 30.6 TSHR TPO TG RET NKX2-1 MET
33 thymic carcinoma 30.6 NKX2-1 MUC1 KRT7
34 gallbladder adenocarcinoma 30.6 MUC1 KRT7 ERBB2
35 renal cell carcinoma, papillary, 1 30.5 RET PBRM1 MET KRT7 ERBB2 BRAF
36 hypoparathyroidism 30.5 TPO RET CALCA
37 squamous cell carcinoma 30.5 NKX2-1 MUC1 KRT7 KRT19 ERBB2 BRAF
38 mesothelioma, malignant 30.5 NKX2-1 MUC1 MET KRT7 KRT20
39 endometrial cancer 30.5 MUC1 MET KRT7 KRT20 ESR1 ERBB2
40 benign teratoma 30.5 TG NKX2-1 KRT7 KRT20
41 oncocytoma 30.5 MUC1 KRT7 KRT20 KRT19
42 subacute thyroiditis 30.4 TSHR TPO TG
43 lung benign neoplasm 30.4 NKX2-1 MET KRT7 KRT20
44 multinodular goiter 30.4 TSHR TPO TG RET NKX2-1 NCOA4
45 nodular goiter 30.4 TSHR TPO TG RET LGALS3 KRT19
46 struma ovarii 30.4 TSHR TG RET NKX2-1 NCOA4 KRT7
47 thyroid gland follicular carcinoma 30.4 TSHR TPO TG RET NKX2-1 NCOA4
48 papillary transitional carcinoma 30.4 KRT7 KRT20
49 cystadenoma 30.4 MUC1 KRT7 KRT20
50 teratoma 30.4 NKX2-1 MUC1 KRT7 KRT20 ESR1 ERBB2

Graphical network of the top 20 diseases related to Papillary Carcinoma:



Diseases related to Papillary Carcinoma

Symptoms & Phenotypes for Papillary Carcinoma

GenomeRNAi Phenotypes related to Papillary Carcinoma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.13 BRAF CALCA CCDC6 CLDN3 CLDN4 ERBB2
2 no effect GR00402-S-2 10.13 BRAF CALCA ERBB2 KRT7 LGALS3 MET

MGI Mouse Phenotypes related to Papillary Carcinoma:

45 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.43 BRAF CALCA CCDC6 CLDN3 CLDN4 ERBB2
2 nervous system MP:0003631 10.3 BRAF CALCA ERBB2 ESR1 KRT19 LGALS3
3 neoplasm MP:0002006 10.29 BRAF CALCA ERBB2 ESR1 KRT19 LGALS3
4 endocrine/exocrine gland MP:0005379 10.27 BRAF CCDC6 ERBB2 ESR1 KRT19 LGALS3
5 normal MP:0002873 10.24 BRAF CALCA CLDN4 ERBB2 ESR1 KRT19
6 cellular MP:0005384 10.22 BRAF CCDC6 CLDN4 ERBB2 ESR1 KRT19
7 behavior/neurological MP:0005386 10.17 BRAF CALCA CLDN3 CLDN4 ERBB2 ESR1
8 renal/urinary system MP:0005367 10.16 BRAF CALCA CLDN4 ESR1 KRT7 LGALS3
9 digestive/alimentary MP:0005381 10.13 BRAF ERBB2 ESR1 KRT19 LGALS3 MET
10 cardiovascular system MP:0005385 10.11 BRAF CALCA CLDN4 ERBB2 ESR1 KRT19
11 limbs/digits/tail MP:0005371 10.1 BRAF ERBB2 ESR1 MET RET TG
12 respiratory system MP:0005388 9.96 BRAF CALCA ERBB2 ESR1 KRT19 LGALS3
13 reproductive system MP:0005389 9.85 BRAF CLDN3 ERBB2 ESR1 KRT19 LGALS3
14 skeleton MP:0005390 9.65 BRAF CALCA ERBB2 ESR1 KRT19 LGALS3
15 mortality/aging MP:0010768 9.47 BRAF CALCA CCDC6 CLDN4 ERBB2 ESR1

Drugs & Therapeutics for Papillary Carcinoma

Drugs for Papillary Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 61)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
BCG vaccine Approved, Investigational Phase 3
2
Mitomycin Approved Phase 3 50-07-7 5746
3 Vaccines Phase 3
4 Adjuvants, Immunologic Phase 3
5 Immunologic Factors Phase 3
6 Anti-Bacterial Agents Phase 3
7 Alkylating Agents Phase 3
8 Antibiotics, Antitubercular Phase 3
9
Aflibercept Approved Phase 2 862111-32-8 124490314
10
Carboplatin Approved Phase 2 41575-94-4 10339178 38904
11
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
12
Trastuzumab Approved, Investigational Phase 2 180288-69-1
13
Hyaluronic acid Approved, Vet_approved Phase 2 9004-61-9 53477741
14
Lenalidomide Approved Phase 1, Phase 2 191732-72-6 216326
15
Durvalumab Approved, Investigational Phase 2 1428935-60-7
16
Tremelimumab Approved, Investigational Phase 2 745013-59-6
17
Pembrolizumab Approved Phase 2 1374853-91-4 254741536
18
Sunitinib Approved, Investigational Phase 2 557795-19-4 5329102
19
Trametinib Approved Phase 2 871700-17-3 11707110
20
Nivolumab Approved Phase 2 946414-94-4
21
Ipilimumab Approved Phase 2 477202-00-9
22
Lenvatinib Approved, Investigational Phase 2 417716-92-8 9823820
23
Iodine Approved, Investigational Phase 2 7553-56-2 807
24
Cediranib Investigational Phase 1, Phase 2 288383-20-0 9933475
25
Maleic acid Experimental, Investigational Phase 1, Phase 2 110-16-7, 110-17-8 444266 444972
26
Cadexomer iodine Experimental Phase 2 94820-09-4
27 Radiopharmaceuticals Phase 2
28 Antiviral Agents Phase 2
29 Antimetabolites Phase 2
30 Fluorodeoxyglucose F18 Phase 2
31 Deoxyglucose Phase 2
32 Endothelial Growth Factors Phase 2
33 Mitogens Phase 2
34 Albumin-Bound Paclitaxel Phase 2
35 Antimitotic Agents Phase 2
36 Tubulin Modulators Phase 2
37 Pharmaceutical Solutions Phase 2
38 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid Phase 2
39 Chelating Agents Phase 2
40 Antineoplastic Agents, Immunological Phase 2
41 Angiogenesis Inhibitors Phase 2
42 Trace Elements Phase 2
43 Anti-Infective Agents Phase 2
44 Anti-Infective Agents, Local Phase 2
45 Micronutrients Phase 2
46 Immunoglobulins Phase 2
47 Immune Checkpoint Inhibitors Phase 2
48 Antibodies, Monoclonal Phase 2
49 Antibodies Phase 2
50 Protein Kinase Inhibitors Phase 2

Interventional clinical trials:

(show all 42)
# Name Status NCT ID Phase Drugs
1 Comparative Study of Intravesical BCG Standard Dose Long-Term Maintenance Versus BCG 1/3 Dose Long-Term Maintenance Versus BCG Standard Dose Short-Term Maintenance Versus BCG 1/3 Dose Short-Term Maintenance in Intermediate and High Risk Ta, T1 Papillary Carcinoma of the Urinary Bladder Completed NCT00002990 Phase 3
2 A Multicenter, Single-Arm Study Evaluating the Efficacy of Synergo® Radiofrequency-Induced Thermochemotherapy Effect (RITE) With Mitomycin C (Synergo® RITE + MMC) in CIS Non-Muscle Invasive Bladder Cancer (NMIBC) Bacillus Calmette-Guérin (BCG)-Unresponsive Patients With or Without Papillary NMIBC Terminated NCT03335059 Phase 3
3 Phase II Study of Cabozantinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Who Progressed on Prior VEGFR-Targeted Therapy Completed NCT01811212 Phase 2 Cabozantinib S-malate
4 Phase 2 Study of Selumetinib Hydrogen Sulfate in Iodine-131 Refractory Papillary Thyroid Carcinoma and Papillary Thyroid Carcinoma With Follicular Elements Completed NCT00559949 Phase 2 Selumetinib
5 A Phase II Study of Single Agent Intravenous (IV) VEGF Trap in Patients With Poor Prognostic Recurrent and/or Metastatic Thyroid Cancer After RAI Therapy Completed NCT00729157 Phase 2
6 Utility of Preoperative FDG-PET/CT Scanning Prior to Primary Chemoradiation Therapy to Detect Retroperitoneal Lymph Node Metastasis in Patients With Locoregionally Advanced Carcinoma of the Cervix (IB2, IIA ≥ 4 CM, IIB-IVA) or Endometrium (Grade 3 Endometrioid Endometrial Carcinoma; Serous Papillary Carcinoma, Clear Cell Carcinoma, or Carcinosarcoma (Any Grade); and Grade 1 OR 2 Endometrioid Endometrial Carcinoma With Cervical Stromal Involvement Overt in Clinical Examination or Confirmed by Endocervical Curettage Completed NCT00416455 Phase 1, Phase 2 ferumoxtran-10
7 Randomized Phase II Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in HER2/Neu+ Patients With Advance/Recurrent Uterine Serous Papillary Carcinoma Completed NCT01367002 Phase 2 Carboplatin/Paclitaxel;Trastuzumab
8 ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID) in the Intravescical Therapy of Patients With Non-muscle Invasive Cancer of the Bladder. A Phase II Marker Lesion. STUDY Completed NCT04661826 Phase 2 Oncofid-P-B
9 Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer Completed NCT01208051 Phase 1, Phase 2 Cediranib;Cediranib Maleate;Lenalidomide
10 A Phase II Study of Durvalumab (MEDI4736) Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma - The DUTHY Trial Recruiting NCT03753919 Phase 2 Durvalumab;Tremelimumab
11 Neoadjuvant Treatment With Selpercatinib in RET-Altered Thyroid Cancers Recruiting NCT04759911 Phase 2 Selpercatinib
12 Treatment of a Long-lasting Radiolabeled Fibroblast Activation Protein Inhibitor 177Lu-DOTA-EB-FAPI in Patients With Radioactive Iodine Refractory Thyroid Cancer Recruiting NCT05410821 Phase 2 177Lu-DOTA-EB-FAPI 1 radionuclide therapy;177Lu-DOTA-EB-FAPI 2 radionuclide therapy;177Lu-DOTA-EB-FAPI 3 radionuclide therapy
13 Pilot Study to Evaluate the Safety and Efficacy of Percutaneous Laser Ablation of Thyroid Papillary Microcarcinoma Recruiting NCT04623801 Phase 2
14 Combination Targeted Therapy With Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers: A Phase II Study Active, not recruiting NCT02973997 Phase 2 Lenvatinib;Lenvatinib Mesylate
15 Phase II Trial of Sunitinib (SU11248) in Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers and Medullary Thyroid Cancers Active, not recruiting NCT00381641 Phase 2 Sunitinib;Sunitinib Malate
16 Randomized Double-Blind Phase II Study of Radioactive Iodine (RAI) in Combination With Placebo or Selumetinib for the Treatment of RAI-Avid Recurrent/Metastatic Thyroid Cancers Active, not recruiting NCT02393690 Phase 2 Selumetinib
17 A Phase 2 Study of Trametinib in Combination With Radioiodine (RAI) for RAS Mutant or RAS/RAF Wild-Type, RAI-Refractory Recurrent and/or Metastatic Thyroid Cancers Active, not recruiting NCT02152995 Phase 2 Trametinib
18 Phase II Study of XL184 (Cabozantinib) in Combination With Nivolumab and Ipilimumab (CaboNivoIpi) in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Whose Cancer Progressed After One Prior VEGFR-Targeted Therapy Active, not recruiting NCT03914300 Phase 2 Cabozantinib S-malate
19 A Phase 2 Study of Lenvatinib in Combination With Radioactive Iodine Therapy in Patients With Progressive RAI-Sensitive Differentiated Thyroid Cancer Terminated NCT03506048 Phase 2 Lenvatinib
20 Phase II Study of Two Dose Levels of Toremifene in the Treatment of Chemotherapy-Resistant Papillary Carcinoma of the Ovary Withdrawn NCT00003865 Phase 2 toremifene
21 Prospective Study on the Clinical Prognosis of Bilateral Central Lymph Node Dissection in the Patients With Unilateral Thyroid Papillary Carcinoma Unknown status NCT02648399
22 Correlation of Malignancy Predictors, Bethesda (I-VI) and TI-RADS Scores (I-V) With Final Histopathology in Patients Undergoing Total Thyroidectomy 34 Years After Chernobyl Disaster: Multi-centric Trial Unknown status NCT04411290
23 Near-infrared (NIR) Fluorescence Imaging With Indocyanine Green (ICG) for Identification of Sentinel Lymph Nodes and Parathyroid Glands During Total Thyroidectomy: Prospective Randomized Clinical Trial Unknown status NCT04424485
24 A Nomogram Model to Predict Central Lymphnode Metastasis in Thyroid Papillary Carcinoma Suitable for Primary Hospitals Completed NCT05191927
25 Study of the Testicular Function After Iodine 131 Therapy in Patients With Papillary Carcinoma Completed NCT01150318 Administration of 131 iodine
26 Pre-Operative Nodal Staging of Thyroid Cancer Using Ultra-Small Superparamagnetic Iron Oxide Magnetic Resonance Imaging (USPIO MRI): Preliminary Study Completed NCT01927887 Ferumoxytol
27 Comparison Between the Axillary Bilateral-breast Approach (ABBA) and Bilateral Axillo-breast Approach (BABA) for Robotic Thyroidectomy Completed NCT02768753
28 Proper Extent of Surgery for Papillary Microcarcinoma Completed NCT01648569
29 Treatment Decision-Making Among Patients Diagnosed With Papillary Microcarcinoma and Their Significant Others Completed NCT01392222
30 A Strategy to Search for Genes Predisposing to Papillary Carcinoma of the Thyroid When Mutated Recruiting NCT02776969
31 Evaluation of F-18 Tetrafluoroborate (18F-TFB) PET/CT in Patients With Differentiated Thyroid Cancer Recruiting NCT05575440
32 Radiofrequency Ablation Use in Thyroid Nodule Recruiting NCT05003856 Early Phase 1
33 Prospective Active Surveillance Versus Surgery in Thyroid Papillary Microcarcinoma Recruiting NCT04129281
34 A Multicenter, Randomized and Controlled Trial of Radiofrequency Ablation vs. Conventional Surgery as Treatment of Papillary Thyroid Microcarcinoma (PTMC) Recruiting NCT03808779
35 Active Surveillance of Papillary Thyroid Microcarcinoma Recruiting NCT02609685
36 RFA Treatment for Papillary Thyroid Microcarcinoma Cohort Recruiting NCT05189821
37 Genomic Predictors of Papillary Microcarcinoma Disease Progression Recruiting NCT02363595
38 Radiofrequency Ablation of Low Risk Papillary Thyroid Microcarcinoma: Safety and Efficacy Recruiting NCT03432299
39 Active Surveillance on Papillary Thyroid Microcarcinoma Active, not recruiting NCT02938702
40 What is the Relation of Microbiome to Papillary Thyroid Microcarcinoma Development? Not yet recruiting NCT04376203
41 A Prospective Randomized Trial Comparing Ultrasound-guided High Intensity Focused Ultrasound (HIFU) Ablation With Active Surveillance (AS) in the Management of Low-risk Papillary Thyroid Microcarcinoma (PTMC) Suspended NCT03327636
42 Effectiveness of Intraoperative Neuromonitoring of the External Branch of the Superior Laryngeal Nerve During Thyroid Surgery Terminated NCT03773120

Search NIH Clinical Center for Papillary Carcinoma

Cochrane evidence based reviews: carcinoma, papillary

Genetic Tests for Papillary Carcinoma

Anatomical Context for Papillary Carcinoma

Organs/tissues related to Papillary Carcinoma:

MalaCards : Thyroid, Lymph Node, Breast, Ovary, Cervix, Endothelial, Salivary Gland

Publications for Papillary Carcinoma

Articles related to Papillary Carcinoma:

(show top 50) (show all 6141)
# Title Authors PMID Year
1
Absence of BRAF, NRAS, KRAS, HRAS mutations, and RET/PTC gene rearrangements distinguishes dominant nodules in Hashimoto thyroiditis from papillary thyroid carcinomas. 53 62
20012784 2010
2
Universal markers of thyroid malignancies: galectin-3, HBME-1, and cytokeratin-19. 53 62
20198455 2010
3
Follicular variant of papillary carcinoma: reproducibility of histologic diagnosis and utility of HBME-1 immunohistochemistry and BRAF mutational analysis as diagnostic adjuncts. 53 62
20042852 2010
4
Adult onset Still's disease diagnosed concomitantly with occult papillary thyroid cancer: paraneoplastic manifestation or coincidence? 53 62
19847590 2010
5
Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma. 53 62
19740516 2010
6
BRAF mutational analysis in papillary carcinomas with mixed follicular and papillary growth patterns. 53 62
19738460 2009
7
Papillary carcinoma of the breast lacks evidence of RET rearrangements despite morphological similarities to papillary thyroid carcinoma. 53 62
19543246 2009
8
COX-2 is induced by HGF stimulation in Met-positive thyroid papillary carcinoma cells and is involved in tumour invasiveness. 53 62
19391129 2009
9
Epigenetic silencing of TTF-1/NKX2-1 through DNA hypermethylation and histone H3 modulation in thyroid carcinomas. 53 62
19506552 2009
10
Development and characterization of a human single-chain antibody fragment against claudin-3: a novel therapeutic target in ovarian and uterine carcinomas. 53 62
19426958 2009
11
The role of immunohistochemistry in the differential diagnosis of papillary lesions of the breast. 53 62
19126567 2009
12
The T1799A BRAF mutation is absent in cribriform-morular variant of papillary carcinoma. 53 62
19415957 2009
13
Immunohistochemical analysis of nm23 protein expression in thyroid papillary carcinoma and follicular neoplasm. 53 62
18996649 2009
14
Differential expression of CK 19 in follicular adenoma, well-differentiated tumour of uncertain malignant potential (WDT-UMP) and follicular variant of papillary carcinoma. 53 62
19213370 2009
15
A case of black thyroid associated with hyalinizing trabecular tumor. 53 62
18753707 2008
16
Coexistence of primary squamous cell carcinoma of thyroid with classic papillary thyroid carcinoma. 53 62
19067856 2008
17
Cytoplasmic and serum galectin-3 in diagnosis of thyroid malignancies. 53 62
18809382 2008
18
Serous carcinoma of the uterus-determination of HER-2/neu status using immunohistochemistry, chromogenic in situ hybridization, and quantitative polymerase chain reaction techniques: its significance and clinical correlation. 53 62
18248390 2008
19
Thyroid peroxidase and galectin-3 immunostaining in differentiated thyroid carcinoma with clinicopathologic correlation. 53 62
18657294 2008
20
Cyclin D1 and p27 expression as prognostic factor in papillary carcinoma of thyroid: association with clinicopathological parameters. 53 62
18925698 2008
21
Potential diagnostic markers in nodular lesions of the thyroid gland: an immunohistochemical study. 53 62
18795075 2008
22
Thyroid carcinoma: molecular pathways and therapeutic targets. 53 62
18437172 2008
23
Claudin-3 and claudin-4 expression in serous papillary, clear-cell, and endometrioid endometrial cancer. 53 62
18313739 2008
24
Split sample comparison of a liquid-based method and conventional smears in thyroid fine needle aspiration. 53 62
18540296 2008
25
[A case of omental mesothelioma presenting with laminar thickening of omentum-appearances of diffuse malignant peritoneal mesothelioma]. 53 62
18408444 2008
26
Expression of cytokeratin 19 in the diagnosis of thyroid papillary carcinoma by quantitative polymerase chain reaction. 53 62
18308654 2008
27
Application of CD56, P63 and CK19 immunohistochemistry in the diagnosis of papillary carcinoma of the thyroid. 53 62
18254952 2008
28
[Galectin-3 in diagnosis of thyroid cancer]. 53 62
18652236 2008
29
Galectin-3 expression in tumor progression and metastasis of papillary thyroid carcinoma. 53 62
18581271 2008
30
Differential expression of dysadherin in papillary thyroid carcinoma and microcarcinoma: correlation with E-cadherin. 53 62
18677652 2008
31
Iodine-123 uptake in vertebral haemangiomas in a patient with papillary thyroid carcinoma. 53 62
19173186 2008
32
HER-2/neu overexpression and amplification in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry, real-time reverse transcription-polymerase chain reaction, and fluorescence in situ hybridization. 53 62
17451461 2008
33
Molecular detection of PPAR gamma rearrangements and thyroid carcinoma in preoperative fine-needle aspiration biopsies. 53 62
18688583 2008
34
The histological diagnosis of metastases to the breast from extramammary malignancies. 53 62
18042689 2007
35
h-caldesmon, calretinin, estrogen receptor, and Ber-EP4: a useful combination of immunohistochemical markers for differentiating epithelioid peritoneal mesothelioma from serous papillary carcinoma of the ovary. 53 62
17667535 2007
36
Diagnostic value of galectin-3, HBME-1, cytokeratin 19, high molecular weight cytokeratin, cyclin D1 and p27(kip1) in the differential diagnosis of thyroid nodules. 53 62
17728499 2007
37
Immunohistochemical staining of papillary breast lesions. 53 62
17525625 2007
38
Prognostic significance of the MUC1 and MUC4 expressions in thyroid papillary carcinoma. 53 62
17473695 2007
39
Activating transcription factor-1-mediated hepatocyte growth factor-induced down-regulation of thrombospondin-1 expression leads to thyroid cancer cell invasion. 53 62
17409099 2007
40
Overexpression of claudin-3 and claudin-4 receptors in uterine serous papillary carcinoma: novel targets for a type-specific therapy using Clostridium perfringens enterotoxin (CPE). 53 62
17326053 2007
41
Double immunostaining with p63 and high-molecular-weight cytokeratins distinguishes borderline papillary lesions of the breast. 53 62
17295644 2007
42
The role of immunohistochemistry for smooth-muscle actin, p63, CD10 and cytokeratin 14 in the differential diagnosis of papillary lesions of the breast. 53 62
16698948 2007
43
Annexin-I as a potential target for green tea extract induced actin remodeling. 53 62
17019707 2007
44
The role of immunolocalization of CD57 and GLUT-1 in cell blocks in fine-needle aspiration diagnosis of papillary thyroid carcinoma. 53 62
16944537 2006
45
Analysis of differential BRAF(V600E) mutational status in multifocal papillary thyroid carcinoma: evidence of independent clonal origin in distinct tumor foci. 53 62
16983703 2006
46
New molecular targeted therapies in thyroid cancer. 53 62
16940797 2006
47
Proteomic identification of new biomarkers and application in thyroid cytology. 53 62
17017437 2006
48
Utility of galectin 3 expression in thyroid aspirates as a diagnostic marker in differentiating benign from malignant thyroid neoplasms. 53 62
17001889 2006
49
GLUT1 and p63 expression in endometrial intraepithelial and uterine serous papillary carcinoma. 53 62
16842248 2006
50
Annexin-1 downregulation in thyroid cancer correlates to the degree of tumor differentiation. 53 62
16627980 2006

Variations for Papillary Carcinoma

Expression for Papillary Carcinoma

Search GEO for disease gene expression data for Papillary Carcinoma.

Pathways for Papillary Carcinoma



Pathways directly related to Papillary Carcinoma:

# Pathway Source
1 Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) Reactome 66

Pathways related to Papillary Carcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.05 MET ESR1 ERBB2 BRAF
2 11.84 MUC1 KRT7 KRT20 KRT19 CLDN3
3 11.58 RET MET ESR1 BRAF
4 10.48 ESR1 ERBB2
5 10.16 RET BRAF
6 10.1 TSHR TPO TG

GO Terms for Papillary Carcinoma

Cellular components related to Papillary Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.7 TSHR TPO RET MUC1 MET ERBB2
2 plasma membrane GO:0005887 9.7 TSHR TPO RET MUC1 MET ERBB2
3 basal plasma membrane GO:0009925 9.63 MET ERBB2 CLDN4
4 apicolateral plasma membrane GO:0016327 9.43 KRT19 CLDN4 CLDN3

Biological processes related to Papillary Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptidyl-tyrosine phosphorylation GO:0018108 9.7 RET MET ERBB2 BRAF
2 positive regulation of metallopeptidase activity GO:1905050 9.26 CLDN4 CLDN3
3 thyroid gland development GO:0030878 9.1 TG NKX2-1 BRAF

Molecular functions related to Papillary Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.43 RET MET ERBB2
2 protein tyrosine kinase activity GO:0004713 9.17 RET MET ERBB2 BRAF

Sources for Papillary Carcinoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....